Overview
On 12 April 1955, University of Michigan auditoriums erupted when Dr. Thomas Francis announced that “the vaccine developed by Dr. Jonas Salk is
90–100 % effective against paralytic polio.” Within 24 h, the 40-year-old researcher became a household name, his face on the cover of
Time magazine and his decision to forgo a patent—saving an estimated
US$7 billion in royalties—elevating him to folk-hero status. Salk’s formalin-killed virus preparation, tested in
1.8 million U.S. schoolchildren during the 1954 Francis Field Trial, slashed annual U.S. polio incidence from
35 000 cases (1953 peak) to fewer than 1 000 by 1963 and laid the groundwork for global eradication campaigns that continue today.
Beyond the bench, Salk fused biomedical research with public philosophy, founding the Salk Institute for Biological Studies (La Jolla, California, 1960) where he championed “a marriage of science and humanism,” exploring immunology, cancer, and even the possibility of an AIDS vaccine until his death on 23 June 1995.
History/Background
Born 28 October 1914 in East Harlem to Russian-Jewish immigrant parents, Salk worked in his mother’s garment shop while excelling at Townsend Harris High School, entering City College of New York at 16 and graduating
cum laude (B.S., chemistry, 1934). Rejected by several medical schools because of Jewish quotas, he earned his M.D. at New York University (1939) and, during a 1941 fellowship at University of Michigan with virologist Dr. Thomas Francis, helped refine
influenza vaccine production using formalin-killed virus—experience that proved pivotal a decade later.
When poliomyelitis surged in post-war summers—58 000 U.S. cases in 1952 alone, leaving 3 000 dead and 21 000 with permanent paralysis—the National Foundation for Infantile Paralysis (March of Dimes) poured US$7.5 million (≈US$85 million today) into vaccine research. Salk, appointed head of the University of Pittsburgh’s Virus Research Laboratory in 1947, pursued a killed-virus approach deemed “too dangerous” by contemporaries like Albert Sabin, who favored live-attenuated oral vaccines. Salk’s logic: killed virus could not revert to virulence, making it safer for mass childhood immunization.
Key Information
-
Breakthrough formulation: 1952–53 Salk combined three poliovirus serotypes grown in
monkey kidney tissue culture (primary rhesus macaque), inactivated with
1:4 000 formalin for 10–12 days at 1 °C, then adsorbed onto
aluminum hydroxide adjuvant to enhance immunogenicity.
-
Francis Field Trial: 1.8 million children aged 6–9, double-blind placebo-controlled;
440 000 received vaccine, 210 000 received placebo, remainder observed—largest medical experiment in history at the time.
-
Efficacy:
90 % against paralytic polio, 60–70 % against all disease, with
11 deaths in vaccinated vs. 33 in placebo group—statistically decisive (p < 0.001).
-
Manufacturing & safety: 1955 Cutter Incident—live virus in lots from Cutter Laboratories caused
204 cases, 11 deaths—led to stricter NIH oversight and Salk’s improved
filtration + 1:8 000 formalin protocol.
-
Global impact: By 1961,
400 million doses distributed worldwide; U.S. cases fell to
161 in 1961 and
zero indigenous wild-type since 1979. WHO estimates Salk-type vaccines still prevent
>650 000 paralysis cases/year.
-
Patent stance: “Could you patent the sun?” Salk replied when asked; he never filed, enabling
royalty-free production and saving an estimated
US$7 billion in licensing fees.
-
Later work: 1960s–80s Salk shifted to
multiple sclerosis auto-immunity,
cancer immunotherapy, and
HIV vaccine concepts, co-authoring
>200 papers and mentoring Nobel laureates Francis Crick and Renato Dulbecco.
Significance
Salk’s vaccine transformed polio from a terrifying summer plague into a textbook example of successful
eradication through vaccination, predating smallpox eradication by two decades. His insistence on safety—killed virus, rigorous inactivation—set
FDA standards for modern vaccines, while his refusal to patent normalized
open-access biomedical knowledge, influencing the 1971
Medicines Patent Pool ethos. The
Salk Institute’s iconic concrete laboratories overlooking the Pacific became a crucible for molecular biology, yielding
Salk’s own work on autoimmune tolerance and, in 2020,
COVID-19 spike-protein structural insights that accelerated mRNA vaccine design. In poll after poll, Americans rank Salk alongside Einstein and Edison, proof that rigorous science married to moral clarity can change the world—one injection at a time.
